ACURA Advisory Group
Terms of Reference
ACURA* Advisory Group
*AbbVie–CARO Uro-Oncologic Radiation Award
This is an advisory group of CARO. It serves to ensure the appropriate and equitable disbursement of funds provided by AbbVie Laboratories to the members defined below.
- To develop a fair, open and equitable mechanism to disburse funds as provided by AbbVie Laboratories, for research in the area of prostate cancer.
- To devise an annual (or as the Advisory Group decide) competition for funds. To advertise the competition to the membership of CARO
- To determine eligibility for the award
- To develop an appropriate schedule for the award cycle
This Advisory Group consists of five members, who are representative of the regions of Canada: British Columbia, Prairie Provinces, Ontario, Quebec and the Eastern Provinces. All categories of membership are eligible for membership. In addition AbbVie will be represented by a Research Director, to be nominated by AbbVie, who will serve as an observer. The Advisory Group members will be appointed by the President of CARO-ACRO.
4. Terms of Office
The term of office of members is three years, renewable.
5. Reporting Relationships
The ACURA Advisory Group reports to the Board of CARO. The Advisory Group will provide an annual written report to the Board and will make a presentation to the membership at the Annual General Meeting.
The Advisory Group will liaise with other Advisory Groups when appropriate.
The Advisory Group will meet at the call of the Chairs, at least annually, and conduct correspondence and teleconferences at the discretion of the chairs.
8. Financial Arrangements
No Advisory Group member shall be remunerated for being or acting as a Advisory Group member. CARO will provide support towards Advisory Group meetings held at the Annual General Meeting or to CARO-ACRO representatives travelling on approved business that is not otherwise supported. It is expected that representatives travelling on approved business, or incurring other additional expenses will be reimbursed by AbbVie in addition to the funds provided for the competition.
This Advisory Group is governed by the By-Laws of CARO.